Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | DRD5 | P21918 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733055 | 1.00 | HTR2A (0.50) | HTR2ADRD2HTR2CSLC6A2SLC6A4 | |
| SCHEMBL28889035 | 0.87 | HTR2A (0.41) | HTR2ADRD2HTR2CSLC6A2SLC6A4 | |
| SCHEMBL15732981 | 0.77 | HTR2A (0.50) | HTR2ADRD2HTR2CSLC6A2SLC6A4 | |
| SCHEMBL30097085 | 0.74 | CHRM2 (0.42) | HTR2AHTR2CHTR2BALDH1A1SIGMAR1 | |
| SCHEMBL8816862 | 0.73 | HTR2A (0.61) | HTR2ADRD2HTR2CSLC6A2SLC6A4 | |
| SCHEMBL29901667 | 0.73 | HTR2A (0.61) | HTR2ADRD2HTR2CSLC6A2SLC6A4 | |
| SCHEMBL29823851 | 0.73 | MAPT (0.48) | ALDH1A1MAPTITGA4 | |
| SCHEMBL819660 | 0.73 | MAPT (0.48) | ALDH1A1MAPTITGA4 | |
| SCHEMBL31538816 | 0.72 | HTR2A (0.50) | HTR2ADRD2HTR2CSLC6A2SLC6A4 | |
| SCHEMBL4576869 | 0.72 | HTR2A (0.50) | HTR2ADRD2HTR2CSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034169-A1 | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4486348-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024217449-A1 | HETEROCYCLIC COMPOUND AS TYK2 INHIBITOR, AND SYNTHESIS AND USE THEREOF | 浙江文达医药科技有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-118804751-A | New compounds and treatment of renal cell carcinoma | 巴什生物技术公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4417606-A1 | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024083208-A1 | KIF18A PROTEIN INHIBITOR | 杭州邦顺制药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2023166153-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034169-A1 | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | HTR2A 4585/4885DRD2 555/4885HTR2C 4195/4885 |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | HTR2A 4539/4885DRD2 4498/4885HTR2C 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.